We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tyratech (DI/S) | LSE:TYR | London | Ordinary Share | COM SHS USD0.001 (DI / REGS) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.95 | 2.70 | 3.20 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMTYR TIDMTYRU
RNS Number : 3765F
TyraTech, Inc.
24 April 2014
24 April 2014
TyraTech, Inc.
("TyraTech" or the "Company")
USA patents for pest control compositions secured
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that the Company has received notice from the United States Patent and Trademark Office ("USPTO") granting two new patents for the Company's novel pest control compositions.
The first patent covers a range of current and pipeline animal health products, including those that will be sold by Novartis Animal Health US, Inc. for the control of flies, cockroaches and other insects in production animal facilities and premises. This patent also covers products sold into the professional pest control and commercial/institutional markets by Envance Technologies, LLC, which is TyraTech's joint venture with AMVAC Chemical Corporation. The patent has a 20-year term, which expires in 2027.
The second patent covers TyraTech's Extend(TM) technology, which harnesses the synergy between natural and synthetic compounds to achieve increased efficacy while reducing the environmental footprint of synthetic pesticides. This patent supports a number of the Company's animal health pipeline products, as well as pipeline products from Envance Technologies. The patent has a 20-year term, which expires in 2029.
The issuance of these patents raises TyraTech's patent portfolio to 21 granted United States and international patents protecting its proprietary screening platform and compositions. The Company currently has 50 United States and international patent applications pending.
Bruno Jactel, Chief Executive Officer, said: "These new patents are a testimony to the quality and innovation behind TyraTech's technology and products. More importantly they will provide protection for TyraTech's products that are already in the market and for products that TyraTech is currently developing. Our research and development teams are continually working to develop new products and formulations that are patentable with the objective of strengthening our growth platform."
For further information please contact:
TyraTech Inc. Alan Reade, Non-Executive Chairman Tel: +44 78 4197 8709 Bruno Jactel, Chief Executive Officer Tel: +1 919 415 4340 SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady Tel: +44 20 3368 3551 Allenby Capital Limited, Joint Broker Chris Crawford Tel: +44 20 3328 5656 Whitman Howard, Joint Broker Ranald McGregor-Smith/ Niall Devins Tel: 44 20 7087 4550 Walbrook, Financial PR and IR Bob Huxford /Guy McDougall (Public Relations) Tel: +44 20 7933 8792 Paul Cornelius (Investor Relations) Tel: +44 20 7933 8794
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIGDSUBDBGSX
1 Year Tyratech Chart |
1 Month Tyratech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
